gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2021-31-3-51-59gastro-j-579Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYПрименение препаратов висмута при синдроме раздраженного кишечникаUse of Bismuth in Irritable Bowel Syndromehttps://orcid.org/0000-0002-2327-5248ИльчишинаТ. А.IlchishinaT. A.

Ильчишина Татьяна Алексеевна — кандидат медицинских наук, врач-гастроэнтеролог.

195279, Санкт-Петербург, пр. Ударников, д. 19/1

Tatyana A. Ilchishina — Cand. Sci. (Med.).

195279, St. Petersburg, Udarnikov ave., 19/1

ita17@mail.ruМногопрофильный медицинский холдинг СМ-КлиникаРоссияSM-Clinic Multispecialty Medical HoldingRussian Federation2021071020213135159Copyright © Ильчишина Т.А., 20212021Ильчишина Т.А.Ilchishina T.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/579Цель обзора

Цель обзора: проанализировать данные о применении препаратов висмута при синдроме раздраженного кишечника.

Основные положения

Основные положения. Синдром раздраженного кишечника (СРК) — распространенное функциональное заболевание, значимо снижающее качество жизни и нарушающее социальное функционирование, в том числе из-за частого симптома — диареи. Постинфекционный СРК может возникать после бактериальной, протозойной или вирусной кишечной инфекции. Предполагается, что эпидемия новой коронавирусной инфекции затрагивает большинство факторов, влияющих на развитие функциональных расстройств, и может служить одной из причин роста постинфекционного подтипа СРК. Соли висмута сочетают в себе цитопротективные, противовоспалительные и антибактериальные свойства. Терапевтическая активность соединений висмута продемонстрирована в лечении различных по этиологии заболеваний, сопровождающихся диареей, в том числе постинфекционной формы СРК. Использование препаратов висмута в терапевтической дозе безопасно и хорошо переносится пациентами.

Заключение

Заключение. Применение препаратов висмута может рассматриваться как один из подходов в лечении и профилактике пациентов с диарейным вариантом СРК, как в виде монотерапии, так и в составе комбинированных схем.

Aim

Aim. An evidence review on use of bismuth in irritable bowel syndrome.

Key points

Key points. Irritable bowel syndrome (IBS) is a common functional disorder significantly impacting the quality of life and social status, i.a., through frequent manifestations of diarrhea. Postinfectious IBS emerges after a bacterial, pro-tozoan or viral intestinal disease. The new coronavirus pandemic supposedly affects most factors involved in functional disorder developments and may serve a fuelling cause of postinfectious IBS. Bismuth salts accumulate cytoprotective, anti-inflammatory and antibacterial properties. Therapeutic efficacy of bismuth compounds has been demonstrated in treatment of diarrhea-accompanied diseases of   various etiology, including postinfectious IBS. The use of therapeutic-dosed bismuth preparations is safe and well tolerated by patients.

Conclusion

Conclusion. Use of bismuth may be considered a treatment and prevention approach in diarrhea-predominant IBS, both in monotherapy and combined regimens.

синдром раздраженного кишечникависмута трикалия дицитратпостинфекционный СРКдиарея Конфликт интересов: публикация выполнена при поддержке компании «КРКА»irritable bowel syndromebismuth tripotassium dicitratepostinfectious IBSdiarrheaReferencesBuono J.L., Carson R.T., Flores N.M. Healthrelated quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35. DOI: 10.1186/s12955-017-0611-2Buono J.L., Carson R.T., Flores N.M. Healthrelated quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017 Feb 14;15(1):35. doi: 10.1186/s12955-017-0611-2.Frändemark Å., Törnblom H., Jakobsson S., Simrén M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am J Gastroenterol. 2018;113(10):1540–9. DOI: 10.1038/s41395-018-0262-xFrändemark Å., Törnblom H., Jakobsson S., Simrén M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am J Gastroenterol. 2018 Oct;113(10):1540-1549. doi: 10.1038/s41395-018-0262-x.Ford A.C., Sperber A.D., Corsetti M., Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675–88. DOI: 10.1016/S0140-6736(20)31548-8Ford A.C., Sperber A.D., Corsetti M., Camilleri M. Irritable bowel syndrome. Lancet. 2020 Nov 21;396(10263):1675-1688. doi: 10.1016/S0140-6736(20)31548-8.Van Oudenhove L., Crowell M.D., Drossman D.A., Halpert A.D., Keefer .L, Lackner J.M., et al. Biopsy-chosocial Aspects of Functional Gastrointestinal Disorders. Gastroenterology. 2016:S0016-5085(16)00218-3. DOI: 10.1053/j.gastro.2016.02.027Van Oudenhove L., Crowell M.D., Drossman D.A., Halpert A.D., Keefer .L, Lackner J.M., et al. Biopsychosocial Aspects of Functional Gastrointestinal Disorders. Gastroenterology. 2016 Feb 18:S0016-5085(16)00218-3. doi: 10.1053/j.gastro.2016.02.027.Grover M., Kolla B.P., Pamarthy R., Mansukhani M.P., Breen-Lyles M., He J.P., et al. Psychological, physical, and sleep comorbidities and functional impairment in irritable bowel syndrome: Results from a national survey of U.S. adults. PLoS One. 2021;16(1):e0245323. DOI: 10.1371/journal.pone.0245323Grover M., Kolla B.P., Pamarthy R., Mansukhani M.P., Breen-Lyles M., He J.P., et al. Psychological, physical, and sleep comorbidities and functional impairment in irritable bowel syndrome: Results from a national survey of U.S. adults. PLoS One. 2021 Jan 14;16(1):e0245323. doi: 10.1371/journal.pone.0245323. .Drossman D.A., Hasler W.L. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastro-enterology. 2016;150(6):1257–61. DOI: 10.1053/j.gastro.2016.03.035Drossman D.A., Hasler W.L. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016 May;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035.Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farru-gia G., Camilleri M., et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042–54.e1. DOI: 10.1053/j.gastro.2016.12.039Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017 Apr;152(5):1042-1054.e1. doi: 10.1053/j.gastro.2016.12.039.Donnachie E., Schneider A., Mehring M., Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a populationlevel study using routinely collected claims data. Gut. 2018;67(6):1078–86. DOI: 10.1136/gutjnl-2017-313713Donnachie E., Schneider A., Mehring M., Enck P. Incidence of irritable bowel syndrome and chronic fatigue following GI infection: a population-level study using routinely collected claims data. Gut. 2018 Jun;67(6):1078-1086. doi: 10.1136/gutjnl-2017-313713.Marshall J.K., Thabane M., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., et al. Eight year prognosis of postinfectious irritable bowel syndrome following water-borne bacterial dysentery. Gut. 2010;59(5):605–11. DOI: 10.1136/gut.2009.202234Marshall J.K., Thabane M., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010 May;59(5):605-11. doi: 10.1136/gut.2009.202234.Pisipati S., Connor B.A, Riddle M.S. Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome. Curr Opin Infect Dis. 2020;33(5):411–8. DOI: 10.1097/QCO.0000000000000666Pisipati S., Connor B.A, Riddle M.S. Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome. Curr Opin Infect Dis. 2020 Oct;33(5):411-418. doi: 10.1097/QCO.0000000000000666.World Health Organization. “Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)”. https://www.who.int/news-room/detail/30-01-2020-statement-onthe-second-meeting-of-the-international-health-regulationsWorld Health Organization. “Statement on the Second Meeting of the International Health Regulations. Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV); 2005.” In URL: Available at: https://www.who.int/news-room/detail/30-01-2020-statement-onthe-second-meeting-of-the-international-health-regulations. 2005.World Health Organization. Mental health and psycho-social considerations during the COVID-19 outbreak, 18 March 2020. World Health Organization; 2020. https://apps.who.int/iris/bitstream/handle/10665/331490/WHO-2019-nCoV-MentalHealth-2020.1-eng.pdfWorld Health Organization. Mental health and psychosocial considerations during the COVID-19 outbreak, 18 March 2020. World Health Organization; 2020. In URL: Available at: https://apps.who.int/iris/bitstream/handle/10665/331490/WHO-2019-nCoV-MentalHealth-2020.1-eng.pdf.Shigemura J., Ursano R.J., Morganstein J.C., Kurosawa M., Benedek D.M. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health conse-quences and target populations. Psychiatry Clin Neurosci. 2020;74(4):281–2. DOI: 10.1111/pcn.12988Shigemura J., Ursano R.J., Morganstein J.C., Kurosawa M., Benedek D.M. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. Psychiatry Clin Neurosci. 2020 Apr;74(4):281-282. doi: 10.1111/pcn.12988.Alzahrani M.A., Alshamrani A.S., Ahmasani I.M., Alahmari F.S., Asiri A.H., Alshehri A.M., et al. Coronavirus disease 2019 pandemic stress and its effects on irritable bowel syndrome patients in Saudi Arabia. Medi-cine (Baltimore). 2020;99(51):e23711. DOI: 10.1097/MD.0000000000023711Alzahrani M.A., Alshamrani A.S., Ahmasani I.M., Alahmari F.S., Asiri A.H., Alshehri A.M., et al. Coronavirus disease 2019 pandemic stress and its effects on irritable bowel syndrome patients in Saudi Arabia. Medicine (Baltimore). 2020 Dec 18;99(51):e23711. doi: 10.1097/MD.0000000000023711.Lazzerini M., Barbi E., Apicella A., Marchetti F., Cardinale .F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020;4(5):e10–1. DOI: 10.1016/S2352-4642(20)30108-5Lazzerini M., Barbi E., Apicella A., Marchetti F., Cardinale .F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020 May;4(5):e10-e11. doi: 10.1016/S2352-4642(20)30108-5.Oshima T., Siah K.T.H., Yoshimoto T., Miura K., Tomita T., Fukui H., et al. Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2020:10.1111/jgh.15346. DOI: 10.1111/jgh.15346Oshima T., Siah K.T.H., Yoshimoto .T, Miura K., Tomita T., Fukui H., et al. Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2020 Nov 16:10.1111/jgh.15346. doi: 10.1111/jgh.15346.Голованова Е.В. Возможности коррекции функциональных расстройств желудочно-кишечного тракта у пациентов с тревожными расстройствами. РМЖ. 2020;6:45–8.olovanova E.V. Treatment modalities for functional gastrointestinal disorders in patients with anxiety disorders. RMJ. 2020;6:45–48. (In Russ.).Ивашкин В.Т., Шептулин А.А., Зольникова О.Ю., Охлобыстин А.В., Полуэктова Е.А., Трухманов А.С. и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. Рос журн гастроэнтерол гепатол колопроктол. 2020;30(3):7–13. DOI: 10.22416/1382-4376-2020-30-3-7Ivashkin V.T., Sheptulin A.A., Zolnikova O.Yu., Okhlobystin A.V., Poluektova E.A., Trukhmanov A.S., et al. New Coronavirus Infection (COVID-19) and Digestive System. Rus J Gastroenterol Hepatol Coloproctol. 2020;30(3):7–13. https://doi.org/10.22416/1382-4376-2020-30-3-7 (In Russ.)Бордин Д.С., Кирюкова М.А., Шенгелия М.И., Колбасников С.В. Инфекция COVID-19 и органы пищеварения. Эффективная фармакотерапия. 2020;16(15):12–6. DOI: 10.33978/2307-3586-2020-16-15-12-16Bordin D.S., Kiriukova M.A., Shengelia M.I., Kolbasnikov S.V. COVID-19 and Gastrointestinal Tract. Effective Pharmacother. 2020;16(15):12–16. https://doi.org/10.33978/2307-3586-2020-16-15-12-16 (In Russ.)Tian Y., Rong L., Nian W., He Y. Review article: gastrointestinal features in COVID-19 and the possi-bility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843–51. DOI: 10.1111/apt.15731Tian Y., Rong L., Nian W., He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020 May;51(9):843-851. doi: 10.1111/apt.15731.Effenberger M., Grabherr F., Mayr L., Schwaerzler J., Nairz M., Seifert M., Hilbe R., et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020;69(8):1543–4. DOI: 10.1136/gutjnl-2020-321388Effenberger M., Grabherr F., Mayr L., Schwaerzler J., Nairz M., Seifert M., Hilbe R., et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020 Aug;69(8):1543-1544. doi: 10.1136/gutjnl-2020-321388.Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y..L, Zhan H., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastro-enterology. 2020;159(3):944–55.e8. DOI: 10.1053/j.gastro.2020.05.048Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y..L, Zhan H., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 Sep;159(3):944-955.e8. doi: 10.1053/j.gastro.2020.05.048.Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gas-troenterology. 2019;156(1):46–58.e7. DOI: 10.1053/j.gastro.2018.07.011Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology. 2019 Jan;156(1):46-58.e7. doi: 10.1053/j.gastro.2018.07.011.Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В., Кравчук Ю.А., Педь В.И. и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;19(4):2630. DOI: 10.15829/1728-8800- 2020-2630Grinevich V.B., Gubonina I.V., Doshchitsin V. L., Kotovskaya Yu.V., Kravchuk Yu.A., Ped V.I., et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. doi:10.15829/1728-8800- 2020-2630 (In Russ.)Schmulson M., Ghoshal U.C., Barbara G. Managing the Inevitable Surge of Post-COVID-19 Functional Gastroin-testinal Disorders. Am J Gastroenterol. 2021;116(1):4–7. DOI: 10.14309/ajg.0000000000001062Schmulson M., Ghoshal U.C., Barbara G. Managing the Inevitable Surge of Post-COVID-19 Functional Gastrointestinal Disorders. Am J Gastroenterol. 2021 Jan 1;116(1):4-7. doi: 10.14309/ajg.0000000000001062.Sun H., Zhang L., Szeto K.Y. Bismuth in medicine. Met Ions Biol Syst. 2004;41:333–78.Sun H., Zhang L., Szeto K.Y. Bismuth in medicine. Met Ions Biol Syst. 2004;41:333-78.Плотникова Е.Ю., Сухих А.С. Препараты висмута в практике врача. Лечащий врач. 2016;2:60–4.Plotnikova E.Yu., Sukhikh A. S. Bismuth drugs in the clinical practice. Lechashchiy_vrach. 2016; 2:60-64 (In Russ.)Thomas F., Bialek B., Hensel R. Medical Use of Bismuth: the Two Sides of the Coin. J Clin Toxicol. 2012;S3:004. DOI: 10.4172/2161-0495.S3-004Thomas, F., Bialek, B. & Hensel, R. Medical Use of Bismuth : the Two Sides of the Coin. J. Clin. Toxicol. 2012, S3-4. doi:10.4172/2161-0495.S3-004.Ge R., Sun H. Bioinorganic chemistry of bismuth and antimony: target sites of metallodrugs. Acc Chem Res. 2007;40(4):267–74. DOI: 10.1021/ar600001bGe R., Sun H. Bioinorganic chemistry of bismuth and antimony: target sites of metallodrugs. Acc Chem Res. 2007 Apr;40(4):267-74. doi: 10.1021/ar600001b.Islam A., Rodrigues B.L., Marzano I.M., Perreira-Maia E.C., Dittz D., Paz Lopes M.T., et al. Cytotoxicity and apoptotic activity of novel organobismuth (V) and organoantimony (V) complexes in different cancer cell lines. Eur J Med Chem. 2016;109:254–67. DOI: 10.1016/j.ej-mech.2016.01.003Islam A., Rodrigues B.L., Marzano I.M., Perreira-Maia E.C., Dittz D., Paz Lopes M.T., et al. Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines. Eur J Med Chem. 2016 Feb 15;109:254-67. doi: 10.1016/j.ejmech.2016.01.003.Yang N., Tanner J.A., Zheng B.J., Watt R.M., He M.L., Lu L.Y., et al. Bismuth complexes inhibit the SARS coro-navirus. Angew Chem Int Ed Engl. 2007;46(34):6464–8. DOI: 10.1002/anie.200701021Yang N., Tanner J.A., Zheng B.J., Watt R.M., He M.L., Lu L.Y., et al. Bismuth complexes inhibit the SARS coronavirus. Angew Chem Int Ed Engl. 2007;46(34):6464-8. doi: 10.1002/anie.200701021.Wolf D.C., Wolf C.H., Rubin D.T. Temporal Improvement of a COVID-19-Positive Crohn’s Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020;115(8):1298. DOI: 10.14309/ajg.0000000000000725Wolf D.C., Wolf C.H., Rubin D.T. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020 Aug;115(8):1298. doi: 10.14309/ajg.0000000000000725.Rendi-Wagner P., Kollaritsch H. Drug prophylaxis for travelers’ diarrhea. Clin Infect Dis. 2002;34(5):628–33. DOI: 10.1086/338640Rendi-Wagner P., Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis. 2002 Mar 1;34(5):628-33. doi: 10.1086/338640.Steffen R. Worldwide efficacy of bismuth subsalicylate in the treatment of travelers’ diarrhea. Rev Infect Dis. 1990;12 (Suppl 1):S80–6. DOI: 10.1093/clinids/12.sup-plement_1.s80Steffen R. Worldwide efficacy of bismuth subsalicylate in the treatment of travelers' diarrhea. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S80-6. doi: 10.1093/clinids/12.supplement_1.s80.Brum J.M., Gibb R.D., Ramsey D.L., Balan G., Yacyshyn B.R. Systematic Review and Meta-Analyses Assess-ment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea. Dig Dis Sci. 2021;66(7):2323–35. DOI: 10.1007/s10620-020-06509-7Brum J.M., Gibb R.D., Ramsey D.L., Balan G., Yacyshyn B.R. Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea. Dig Dis Sci. 2020 Aug 8. doi: 10.1007/s10620-020-06509-7.Budisak P., Abbas M. Bismuth Subsalicylate. [Updated 2020 Nov 26]. In: StatPearls. Treasure Island (FL): Stat-Pearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560697/Budisak P, Abbas M. Bismuth Subsalicylate. [Updated 2020 Nov 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560697/.Pitz A.M., Park G.W., Lee D., Boissy Y.L., Vinjé J. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93–100. DOI: 10.1080/19490976.2015.1008336Pitz A.M., Park G.W., Lee D., Boissy Y.L., Vinjé J. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93-100. doi: 10.1080/19490976.2015.1008336.Senderovich H., Vierhout M. Is There a Role for Bismuth in Diarrhea Management? Rambam Maimonides Med J. 2021;12(1):e0002. Published 2021 Jan 19. DOI: 10.5041/RMMJ.10422Senderovich H., Vierhout M. Is There a Role for Bismuth in Diarrhea Management?. Rambam Maimonides Med J. 2021;12(1):e0002. Published 2021 Jan 19. doi:10.5041/RMMJ.10422.Осипенко М.Ф., Бикбулатова Е.А. Синдром диареи и препараты висмута. Эффективная фармакотерапия в гастроэнтерологии. 2008;1:42–7.Osipenko M. F., Bikbulatova E. A. Diarrhea syndrome and bismuth preparations. Effective pharmacother. in gastroenterol. 2008; 1: 42-47. (In Russ.).Пушкина А.В., Авалуева Е.Б., Данилова И.А., Лапинский И.В., Ткаченко Е.И., Сказываева Е.В. и др. Использование препарата висмута трикалия дицитрата в лечении синдрома раздраженного кишечника с преобладанием диареи. Лечащий врач, 2016;6:81–5.Pushkina A.V., Avalueva E.B., Danilova I.A., Lapinskiy I.V., Tkachenko E.I., Skazyvaeva E.V. Treatment of irritable bowel syndrome with prevalence of diarrhea by bismuth tripotassium dicitrate. Lechashchiy_vrach. 2016; 6:81-85 (In Russ.)Парфенов А.И., Ручкина И.Н., Осипов Г.А. Висмута трикалия дицитрат в лечении больных постинфекцион-ным СРК с преобладанием диареи. РМЖ. 2006;2:3–6.Parfenov A.I., Ruchkina I.N., Osipov G.A. Bismuth tripotassium dicitrate in the treatment of patients with post-infectious IBS with a predominance of diarrhea RMJ. 2006;2:3–6. (In Russ.)Яковенко Э.П., Агафонова Н.А., Похальская О.Ю., Колганова А.В., Нахарбекова Р.С., Иванов А.П. и др. Применение висмута трикалия дицитрата (денола) — перспективное направление в патогенетической терапии синдрома раздраженного кишечника с диареей. Клин мед. 2008;10:47–52.Yakovenko E.P., Agafonova N.A., Pokhal'skaya О. Yu., Kolganova A.V., Nakharbekova R.S., Ivanov A.N. et al. The use of bismuth tripotassium dicitrate (denol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea. Klin. Med. 2008; 10: 47–52. (In Russ.).Alavinejad P., Hashemi S.J., Hajiani E. Low Dose Mesalazine Plus Bismuth Regimen and Symptoms of Irritable Bowel Syndrome in Patients with Bloating: A Quasi-Experimental Study. Jundishapur J Chronic Dis Care. 2016;5(4):e35043. DOI: 10.17795/jjcdc-35043Alavinejad P, Hashemi S J, Hajiani E. Low Dose Mesalazine Plus Bismuth Regimen and Symptoms of Irritable Bowel Syndrome in Patients with Bloating: A Quasi-Experimental Study, Jundishapur J Chronic Dis Care. 2016; 5(4):e35043. doi: 10.17795/jjcdc-35043.Daghaghzadeh H., Memar A., Mohamadi Y., Rezakhani N., Safazadeh P., Aghaha S.A., et al. Therapeutic Effects of Lowdose Bismuth Subcitrate on Symptoms and Health-related Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical Trial. J Res Pharm Pract. 2018;7(1):13–21. DOI: 10.4103/jrpp.JRPP_17_56Daghaghzadeh H., Memar A., Mohamadi Y., Rezakhani N., Safazadeh P., Aghaha S.A., et al. Therapeutic Effects of Lowdose Bismuth Subcitrate on Symptoms and Healthrelated Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical Trial. J Res Pharm Pract. 2018 Jan-Mar;7(1):13-21. doi: 10.4103/jrpp.JRPP_17_56.Хомерики Н.М., Морозов И.А. Особенности цитопротекции в желудке и некоторые аспекты фармакологического действия препаратов висмута. Медицинский Совет. 2017;11:112–9. DOI: 10.21518/2079-701X-2017-11-112-119Khomeriki N.M., Morozov I.A. Peculiarities of cytoprotection in the stomach and some aspects of pharmacological action of bismuth drugs. Meditsinskiy sovet = Medical Council. 2017;(11):112-119. https://doi.org/10.21518/2079-701X-2017-11-112-119 (In Russ.)Konturek S.J., Radecki T., Piastucki I., Brzozowski T., Drozdowicz D. Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut. 1987;28(2):201–5. DOI: 10.1136/gut.28.2.201Konturek S..J, Radecki T., Piastucki I., Brzozowski T., Drozdowicz D. Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins. Gut. 1987 Feb;28(2):201-5. doi: 10.1136/gut.28.2.201.Cavicchi M., Gibbs L., Whittle B.J. Inhibition of inducible nitric oxide synthase in the human intestinal epithelial cell line, DLD-1, by the inducers of heme oxygenase 1, bismuth salts, heme, and nitric oxide donors. Gut. 2000;47(6):771–8. DOI: 10.1136/gut.47.6.771Cavicchi M., Gibbs L., Whittle B.J. Inhibition of inducible nitric oxide synthase in the human intestinal epithelial cell line, DLD-1, by the inducers of heme oxygenase 1, bismuth salts, heme, and nitric oxide donors. Gut. 2000 Dec;47(6):771-8. doi: 10.1136/gut.47.6.771.Pullan R.D., Ganesh S., Mani V., Morris J., Evans B.K., Williams G.T., et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut. 1993;34(5):676–9. DOI: 10.1136/gut.34.5.676Pullan R.D., Ganesh S., Mani V., Morris J., Evans B.K., Williams G.T. et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut. 1993 May;34(5):676-9. doi: 10.1136/gut.34.5.676.Ryder S.D., Walker R.J., Jones H., Rhodes J.M. Rectal bismuth subsalicylate as therapy for ulcerative colitis. Ali-ment Pharmacol Ther. 1990;4(4):333–8. DOI: 10.1111/j.1365-2036.1990.tb00480.xRyder S.D., Walker R.J., Jones H., Rhodes J.M. Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther. 1990 Aug;4(4):333-8. doi: 10.1111/j.1365-2036.1990.tb00480.x.Fine K.D., Lee E.L. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gas-troenterology. 1998;114(1):29–36. DOI: 10.1016/s0016-5085(98)70629-8Fine K.D., Lee E.L. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology. 1998 Jan;114(1):29-36. doi: 10.1016/s0016-5085(98)70629-8.Phillips R.H., Whitehead M.W., Lacey S., Champion M., Thompson R.P., Powell J.J. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy. Helicobacter. 2000;5(3):176– 82. DOI: 10.1046/j.1523-5378.2000.00028.xPhillips R.H., Whitehead M.W., Lacey S., Champion M., Thompson R.P., Powell J.J. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy. Helicobacter. 2000 Sep;5(3):176-82. doi: 10.1046/j.1523-5378.2000.00028.x.Висмутсодержащие препараты в гастроэнтерологии. Здоровье Украины. 2009;13–14:64–5.Bismuthcontaining drugs in gastroenterology. Overview. Health of Ukraine. 2009; 13-14: 64-65. (In Russ.).Симаненков В.И., Бакулина Н.В., Тихонов С.В. Препараты висмута трикалия дицитрата: от фармацевтических характеристик к клинической эффективности. Медицинский алфавит. 2019;1(6):23–8. DOI: 10.33667/2078-5631-2019-1-6(381)-23-28Simanenkov V.I., Bakulina N.V., Tikhonov S.V. Bismuth tripotassium dicitrat: from pharmaceutical characteristics to clinical efficacy. Medical alphabet. 2019;1(6):23-28. https://doi.org/10.33667/2078-5631-2019-1-6(381)-23-28 (In Russ.).

The authors declare that there are no conflicts of interest present.